Last reviewed · How we verify
BCG vial vaccine
Stimulates a cell-mediated immune response against Mycobacterium tuberculosis
Stimulates a cell-mediated immune response against Mycobacterium tuberculosis Used for Tuberculosis.
At a glance
| Generic name | BCG vial vaccine |
|---|---|
| Sponsor | PT Bio Farma |
| Drug class | Live attenuated vaccine |
| Modality | Biologic |
| Therapeutic area | Infectious Disease |
| Phase | Phase 2 |
Mechanism of action
BCG vaccine works by introducing a weakened form of the tuberculosis bacteria to the body, which triggers an immune response that helps protect against future infections.
Approved indications
- Tuberculosis
Common side effects
- Local reaction
- Fever
Key clinical trials
- Evaluating the Safety and Immunogenicity of MTBVAC (PHASE2)
- Can BCG Vaccination at First Health-facility Contact Reduce Early Infant Mortality? (PHASE4)
- Safety, Immunogenicity, and Efficacy of Therapeutic Mycobacterium Bovis BCG (BOOST) (PHASE2)
- Safety and Immunogenicity of a Mycobacterium Tuberculosis Vaccine MTBVAC in Healthy Indian Adults and Adolescents (BBV169/2024) (PHASE2)
- Tuberculosis Vaccine in Healthy Indian Adults (PHASE1)
- Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa (PHASE3)
- Evaluation of Efficacy and Safety of VPM1002 in Comparison to BCG in Prevention of Tb Infection in Infants (PHASE3)
- Bacille Calmette-Guérin (BCG) Vaccine In Radiologically Isolated Syndrome (RIS) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BCG vial vaccine CI brief — competitive landscape report
- BCG vial vaccine updates RSS · CI watch RSS
- PT Bio Farma portfolio CI